Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells

Gynecological Endocrinology

Volumn 28, Issue 11, 2012, Pages 863-866

  Ruan, Xiangyan ^a   Schneck, Helen ^b   Schultz, Silke ^b   Fehm, Tanja ^b   Cahill, Michael A ^c   Seeger, Harald ^b   Chen, Rong ^d   Yu, Qi ^d   Mueck, Alfred O ^b   Neubauer, Hans ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c CHARLES STURT UNIVERSITY   (Australia)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Breast cancer cells; Progesterone; Progesterone receptor membrane component 1; Proliferation; Synthetic progestogens

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MEDROXYPROGESTERONE ACETATE; MEMBRANE RECEPTOR; MIFEPRISTONE; NOMEGESTROL ACETATE; NORETHISTERONE; PROGESTERONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST; BREAST NEOPLASMS; CELL PROLIFERATION; CONTRACEPTIVES, ORAL, HORMONAL; FEMALE; HUMANS; MCF-7 CELLS; MEGESTROL; MEMBRANE PROTEINS; NORPREGNADIENES; RECEPTORS, PROGESTERONE; STEROIDS;

EID: 84867540206     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2012.671396     Document Type: Article

References (18)

1. Mueck AO, Sitruk-Ware R. Nomegestrol acetate, a novel progestogen for oral contraception. Steroids 2011;76:531-539.
2. Ruan X, Seeger H, Mueck AO. The pharmacology of nomegestrol acetate. Maturitas 2012;71:345-353.
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-333.
4. Seeger H, Mueck AO. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. J Steroid Biochem Mol Biol 2008;109:11-15.
5. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111.
6. Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. The effect of progesterone, testosterone and synthetic progestogens on growth factor- and estradiol-treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod 2006; 27: 139-141.
7. Neubauer H, Yang Y, Seeger H, Fehm T, Cahill MA, Tong X, Ruan X, Mueck AO. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause 2011;18:845-850.
8. Stanczyk FZ. Can the increase in breast cancer observed in the estrogen plus progestin arm of the Women's Health Initiative trial be explained by progesterone receptor membrane component 1? Menopause 2011;18:833-834.
9. Neubauer H, Clare SE, Wozny W, Schwall GP, Poznanovic S, Stegmann W, Vogel U, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008; 10:R85.
10. Cahill MA. Progesterone receptor membrane component 1: An integrative review. J Steroid Biochem Mol Biol 2007;105: 16-36.
11. Neubauer H, Adam G, Seeger H, Mueck AO, Solomayer E, Wallwiener D, Cahill MA, Fehm T. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009;12:230-239.
12. Neubauer H, Chen R, Schneck H, Knorrp T, Templin MF, Fehm T, Cahill MA, Seeger H, Yu Q, Mueck AO. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Invest 2011;6:185-192.
13. Ruan X, Neubauer H, Yang Y, Schneck H, Schultz S, Fehm T, Cahill MA, Seeger H, Mueck AO. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells, Climacteric, Feb 15. [Epub ahead of print]
14. Chetrite GS, Thomas JL, Shields-Botella J, Cortes-Prieto J, Philippe JC, Pasqualini Jr. Control of sulfatase activity by nomegestrol acetate in normal and cancerous human breast tissues. Anticancer Res 2005;25:2827-2830.
15. Shields-Botella J, Chetrite G, Meschi S, Pasqualini Jr. Effect of nomegestrol acetate on estrogen biosynthesis and transformation in MCF-7 and T47-D breast cancer cells. J Steroid Biochem Mol Biol 2005;93:1-13.
16. Chetrite GS, Pasqualini Jr. Nomegestrol acetate is an anti-aromatase agent in human MCF-7aro breast cancer cells. Horm Mol Biol Clin Invest 2010; 3: 417-424.
17. Mueck AO, Ruan X. Benefits and risks during HRT-main safety issue breast cancer. Horm Mol Biol Clin Invest 2011;5:105-116
18. Merki-Feld GS, Seeger H, Mueck AO. Proliferative effects of estradiolor ethinylestradiol-progestogen combinations on human breast cancer cells in an intermitted and a long-term regimen. Horm Metab Res 2012, accepted.